Drug delivery company Monosol Rx and partner Reckitt Benckiser Pharmaceuticals have received US Food and Drug Administration (FDA) clearance to market a sublingual film formulation of the opioid dependence treatment Suboxone.
US formulation services provider Bend Research has received a new patent for the process of producing spray-dried solid amorphous dispersions of drugs using single-fluid pressure nozzles.
RecipharmCobra Biologics has received US and EU patent protection for an antibiotic resistance gene-free plasmid maintenance technology it claims can boost biomanufacturing yields.
NanGenex is introducing GMP bench-top and pilot plant reactors to scale-up its process for the continuous production of nanostructured active ingredients.
Cell culture, LAIV vaccines and recombinant DNA technology should be supported by the US government as part of a long-term overhaul of pandemic response capabilities, according to PCAST.
India is considering strengthening compulsory licensing provisions, which allow third parties to produce patented products, in response to concerns about overseas takeovers and drug prices.
Cell penetration and pharmacodynamics boosting “stapled peptide” tech wins Aileron Therapeutics potential billion dollar protein drug development deal with Roche.
Stirling Pharma’s state-of-the-art Canadian plant will open its doors in late September, and first to come off the production line will be the drug, acetaminophen.
The FDA has approved Alexion Pharmaceuticals’ Rhode Island, US plant for commercial supply of Soliris (eculizumab), giving the biopharm a second source.
Chemir Analytical Services launches custom synthesis service for organic molecules for drug R&D, aimed at small pharma companies with rush or emergency projects.
The US HHS is allocating $2bn (€1.6bn) to overhaul pandemic and bioterrorism capabilities through improvements to regulatory, developmental and manufacturing processes.
SAFC and Novozymes Biopharma have agreed to extend their partnership by ten years for the exclusive distribution of LONG R3 growth factor, used for industrial cell culture applications.
Producing conjugate vaccines in recombinant E coli is potentially simpler and more cost-effective than alternatives, say researchers, but the method suffers from low yields.
US drugmaker Merck & Co has announced plans to reacquire a Pennsylvania manufacturing plant to guarantee supply of key active pharmaceutical ingredient (API).
Lower overseas demand from key customers hurt fine chemicals maker Synthetech in first quarter fiscal 2011, continuing the decline seen in the previous financial year
Respiratory formulations specialist Vectura has licensed two dry-formulation technologies to GSK, further strengthening its position in the $25bn (€19bn) asthma and COPD market.
Penwest Pharmaceuticals raises guidance citing Opana ER royalties, deals and patent settlements as Q2 highlights; but warns that job cuts likely under cost cutting plan.
Ampac Fine Chemicals posted a 28 per cent jump in revenues in the third quarter but this was offset by manufacturing inefficiencies and validation costs.
Pfenex has won a US federal contract to use its expression technology for the rapid, cost-effective production of “unprecedented” amounts of anthrax vaccine.
Greater recognition of toxicity risks of HPAPIs and continued growth of oncology sector are driving drug industry demand for safe manufacturing capacity says US fine molecules firm SAFC Pharma.
Recently-acquired Italian R&D facility helps Aptuit win new contract after local neuroscience-focused developer Siena Biotech names the CMO as “supplier of choice.”
Colorcon will buy Indian group Pharmaceuitcal Coatings to expand both its tablet film coating business and presence in “rapidly growing” pharmaceutical market.